default author photo

Lisa M. Dunkle

Novavax, Inc.

SCHOLARLY PAPERS

2

DOWNLOADS

254

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Risk of COVID-19 after Natural Infection or Vaccination

Number of pages: 24 Posted: 01 May 2023
University of Pittsburgh - Department of Pediatrics, University of Maryland, Baltimore (UMB) - School of Medicine, Fred Hutchinson Cancer Research Center, affiliation not provided to SSRN, Fred Hutchinson Cancer Research Center, University of California, San Diego (UCSD) - Division of Infectious Diseases and Global Public Health, University of South Florida - Morsani College of Medicine, Emory University School of Medicine and Children’s Healthcare of Atlanta - Department of Pediatrics, Ndlovu Research Centre, Harvard University - Brigham and Women’s Hospital, Baylor College of Medicine, Instituto Nacional de Infectologia Evandro Chagas, Fiocruz - Lab. De Pesquisa Clinica DST/AIDS, South African Medical Research Council, University of North Carolina (UNC) at Chapel Hill - School of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Moderna, Inc., AstraZeneca Pharmaceuticals, Janssen Research & Development, LLC, Novavax, Inc., - Center for Vaccine Development and Global Health, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Alabama at Birmingham - Heersink School of Medicine, Harvard University - Brigham and Women’s Hospital, Government of the United States of America - Biostatistics Research Branch and - Department of Pediatrics
Downloads 229 (334,744)

Abstract:

Loading...

COVID-19, natural infection, hybrid immunity, vaccination

2.

Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials

Number of pages: 30 Posted: 10 Jan 2026
Fred Hutchinson Cancer Research Center, University of Illinois Chicago, University of Pittsburgh - Department of Pediatrics, University of Maryland, Baltimore (UMB) - School of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of North Carolina (UNC) at Chapel Hill - School of Medicine, Harvard University - Brigham and Women’s Hospital, University of Alabama at Birmingham - Heersink School of Medicine, Emory University, Baylor College of Medicine, South African Medical Research Council, Instituto Nacional de Infectologia Evandro Chagas, Fiocruz - Lab. De Pesquisa Clinica DST/AIDS, Columbia University - Aaron Diamond AIDS Research Center, University of Rochester, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Government of the United States of America - Biostatistics Research Branch, National Institutes of Health - Vaccine Research Center, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Novavax, Inc., Sanofi - Pennsylvania, affiliation not provided to SSRN, - Center for Vaccine Development and Global Health, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Harvard University - Brigham and Women’s Hospital, - Department of Pediatrics and Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division
Downloads 25 (1,436,435)

Abstract:

Loading...

(3-10): COVID-19, SARS-CoV-2, antibody, Vaccination, immunity, natural immunity, hybrid immunity, correlate of protection, Efficacy